Introduction

The fecal occult blood test (FOBT) is a diagnostic modality for detecting microscopic blood in stool, primarily employed in colorectal cancer (CRC) screening. CRC ranks among the most prevalent malignancies in men and women worldwide, and early detection significantly reduces associated morbidity and mortality.[1] The fecal immunochemical test (FIT), a newer method, utilizes antibodies to detect human hemoglobin and has largely supplanted FOBT due to superior specificity, enhanced sensitivity, and lower cost.[2]

Blood entering the upper gastrointestinal tract undergoes complete digestion of the globin portion of hemoglobin by proteolytic enzymes. Heme is converted by bacterial action into porphyrins. Hemoglobin reaching the lower intestine is largely undigested. In healthy individuals, gastrointestinal blood loss typically ranges from 0.5 to 1.5 mL per day, below the detection threshold of standard FOBTs.[3]

Detection methods are based on the identification of hemoglobin or its degradation products.[4] Fecal blood may also be identified via macroscopic examination for erythrocytes or hematin crystals or spectroscopic analysis of hemoglobin and its derivatives.[5]

Specimen Collection

FOBT may be performed in both inpatient and outpatient settings. In the inpatient setting, stool may be obtained manually during digital rectal examination and applied to heme occult testing cards. In the outpatient setting, the patient typically collects a stool sample at home and submits it to a laboratory.[6]

Sampling should occur prior to contact with toilet water, as hemoglobin may leach from the specimen, and toilet sanitizers can interfere with results. Blood is not uniformly distributed within feces, and gastrointestinal bleeding may be intermittent. Therefore, samples should be collected from multiple areas and repeated on 3 separate days.[7]

Specimens should be protected from extreme heat and humidity. Dried samples may be stored at room temperature for up to 14 days.[8] Delays between collection and analysis may result in false-negative results due to degradation of the pseudoperoxidase activity of heme in moist feces. Collection directly onto filter paper in the test kit, followed by drying, prevents this degradation.[9]

Certain immunological methods employ collection devices containing liquid preservatives, allowing sample application by smearing feces onto the provided card.[10] Patient preparation is necessary for optimal results. Samples should not be collected in the presence of visible blood in stools or urine, including conditions such as menstruation, active hemorrhoids, and urinary tract infection.

Procedures

Verification of the FOBT card and developer for expiration before stool collection and testing is essential. Clinical laboratory tests commonly detect hemoglobin, heme, or heme-derived porphyrins.[11] Hemoglobin is identified via immunological methods, heme via guaiac-based methods exploiting the pseudoperoxidase activity of heme, and porphyrins via fluorimetric analysis.[12]

The predominant method for detecting fecal occult blood is based on heme detection. In these assays, the pseudoperoxidase activity of heme catalyzes the liberation of nascent oxygen from hydrogen peroxide.[13] The liberated oxygen subsequently oxidizes a chromogen. Historically employed chromogens include benzedrine and o-toluidine. Although sensitive, these compounds are carcinogenic and are no longer utilized in clinical laboratories. Alternative chromogens such as imipramine hydrochloride and desipramine hydrochloride have been used, with guaiac, a natural resin extracted from Guaiacum officinale, representing the most commonly employed chromogen in contemporary testing.[14] The sensitivity of the guaiac-based method is lower than that of o-toluidine. However, the incorporation of stabilizers has enhanced the sensitivity of this technique.[15]

These tests utilize a card containing high-quality filter paper impregnated with guaiac, which remains stable over extended periods as the guaiac is not in solution.[16] The developing solution consists of stabilized hydrogen peroxide in an aqueous alcoholic medium. Hemoglobin and its iron-containing degradation products catalyze the release of oxygen from hydrogen peroxide via pseudoperoxidase activity. The liberated oxygen subsequently oxidizes α-guaiaconic acid, a phenolic compound present in guaiac.[17] The reaction produces a quinone structure that rearranges to a blue dye through internal electron transfer.

Immunological methods exhibit higher specificity by employing antibodies targeting blood components, most commonly the globin chain of hemoglobin.[18] Hemoglobin forms a complex with a conjugate composed of a monoclonal or polyclonal antibody linked to a dye or enzyme, which generates a colored product from the substrate within the system.[19] Various immunochemical detection systems have been described, including enzyme immunoassays, hemagglutination, latex agglutination, and colloidal gold agglutination assays.[20]

Numerous commercial kits have been developed for the detection of blood using immunochemical methods, with some systems fully automated, resulting in increased reproducibility.[21] Immunochemical assays may be conducted in hospitals, at home, or in clinical laboratories.[22] These methods do not require dietary restrictions and exhibit greater sensitivity, with lower detection limits compared with guaiac-based methods. Automated systems further enhance reproducibility by eliminating the subjectivity associated with visual result interpretation. Immunochemical methods can detect as little as 0.3 mL of blood added to stool and demonstrate increased specificity for lower gastrointestinal tract bleeding, particularly from the colon, as globin from hemoglobin in the upper gastrointestinal tract is hydrolyzed by proteolytic enzymes.

One device employs a combination of immunological and guaiac-based approaches. Hemoglobin is immobilized by a monoclonal antibody and subsequently visualized using the guaiac-based reaction. Nonhemoglobin peroxidases may produce a background blue color, which is disregarded in result interpretation.[23]

The heme-porphyrin test is based on the conversion of heme in hemoglobin entering the gastrointestinal tract to porphyrins, likely mediated by gut bacteria. In this assay, porphyrins are extracted from feces and quantified using spectrofluorimetry.[24] This approach allows precise quantitation of hemoglobin entering the gastrointestinal tract and demonstrates superior sensitivity for detecting bleeding in the upper gastrointestinal tract.[25] Guaiac-based and immunological methods are less reliable for upper gastrointestinal tract bleeding, as hemoglobin may be degraded by proteolytic enzymes within the gut.[26]

A recently described method employs matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF-MS). In this technique, the fecal sample is mixed with water, ultrasonicated, and centrifuged. The resulting supernatant is combined with a matrix solution for MALDI-TOF-MS analysis.[27] Blood is identified by the detection of water-soluble α- and β-globin chains. This method is 10- to 100-fold more sensitive than conventional assays and is not affected by plant peroxidases or dietary red meat.[28] Although highly sensitive, with a lower detection limit of 0.01 mg/g feces, MALDI-TOF-MS has not been validated for routine screening, and its high cost limits practicality in most clinical laboratories.

Indications

The primary indications for FOBT include evaluation of anemia, assessment for gastrointestinal bleeding, and CRC screening. FOBT may also assist in distinguishing irritable bowel syndrome from inflammatory bowel disease, the latter being more likely to produce a positive result.

Potential Diagnosis

Occult fecal blood may arise from multiple etiologies. Neoplastic causes include adenocarcinoma, gastrointestinal metastases, lymphoma, and leiomyosarcoma.[29] Inflammatory sources encompass Crohn disease, ulcerative colitis, gastritis, peptic ulcer disease, and diverticular bleeding.[30] Vascular pathologies include angiodysplasia, venous ectasia, variceal bleeding, hemangioma, gastric antral vascular ectasia, and Dieulafoy lesions.[31] Infectious etiologies comprise Salmonella species, enteroinvasive and enterohemorrhagic Escherichia coli, Shigella species, Neisseria species, Yersinia species, Mycobacterium tuberculosis, Campylobacter species, and Strongyloides infections.[32]

Normal and Critical Findings

An FOBT card that does not develop a blue color is interpreted as negative. A blue color change indicates a positive result, necessitating further gastroenterological evaluation.

Normal fecal blood loss can reach up to 1.5 mL per day, as measured using radiochromium (51Cr-labeled red cells) techniques.[33] In patients with benign adenomas or colorectal carcinoma, bleeding is often microscopic but may exceed 1.5 mL per day.[34] Bleeding may be intermittent. Therefore, distinguishing normal from pathological blood loss solely by fecal quantification is not always feasible.[35] Additionally, the volume of blood loss from tumors may vary daily, and hemoglobin and its degradation products are distributed nonuniformly throughout the feces.[36][37]

Peptic ulcers, hemorrhoids, and diverticula also contribute to fecal occult blood loss, with variable bleeding intensity. Among available methods, heme-porphyrin testing demonstrates superior sensitivity for detecting small volumes of upper gastrointestinal tract bleeding, such as that induced by aspirin.[38]

FOBT is employed to detect gastrointestinal bleeding and is most commonly utilized as a screening modality for CRC, one of the most prevalent malignancies worldwide. Numerous studies have evaluated the efficacy of FOBT for early detection of CRC.

FOBT is also a critical diagnostic tool in patients with iron-deficiency anemia to exclude gastrointestinal bleeding as the underlying cause. Selection of the appropriate test is essential since bleeding from any segment of the gastrointestinal tract can induce iron deficiency.[39] Guaiac-based and immunological methods are less sensitive for detecting upper gastrointestinal tract bleeding. Heme-porphyrin testing demonstrates superior sensitivity in this context, detecting approximately 90% of upper gastrointestinal tract bleeding and identifying blood loss as low as 5 mL per day.[40]

Interfering Factors

FOBT requires medication and dietary restrictions prior to testing to reduce the risk of false-negative and false-positive results.[41] Numerous studies have assessed factors contributing to these erroneous results. A retrospective study evaluated medications associated with false-positive outcomes and recommended avoiding these agents, when possible, for 7 days before testing.[42] Medications identified include acetylsalicylic acid, unfractionated or low-molecular-weight heparin, warfarin, clopidogrel, nonsteroidal anti-inflammatory drugs, and selective serotonin reuptake inhibitors. The study reported that 10.9% of patients with positive FOBT results and no dietary or medication restrictions prior to testing demonstrated normal findings on follow-up endoscopic evaluation.[43]

Dietary avoidance for 3 days before FOBT further mitigates the risk of false results. Improper sample collection in patients with hematuria or menstruation may also generate false-positive results.

Guaiac-based methods are susceptible to interference from multiple sources, including plant peroxidases. Raw fruits and vegetables, such as turnips, broccoli, horseradish, cauliflower, cantaloupe, parsnip, and red radish, contain high concentrations of peroxidases.[44] These enzymes are heme proteins with a prosthetic group of ferri-protoporphyrin IX (hemin) and can induce false-positive results in guaiac-based tests. Cooking vegetables at 100 °C for 20 minutes has been shown to inactivate plant peroxidase activity.[45]

Gastric acid denatures peroxidases. Therefore, ingestion of raw vegetables is unlikely to affect test results in individuals with normal gastric acid secretion.[46] Consumption of 750 g of raw, peroxidase-rich fruits and vegetables daily can lead to false-positive results, though this amount of raw produce is unusually large for daily intake.[47] Delaying slide development by 48 hours can reduce interference from plant peroxidases. However, many manufacturers of guaiac-based tests recommend avoiding high-peroxidase-containing fruits and vegetables before and during sample collection.

Ingestion of red meat can produce false-positive results in FOBT due to the peroxidase activity of heme.[48] The false-positive rate is increased when rehydration is performed before analysis. Residual peroxidase activity may persist even after cooking. Studies in healthy volunteers indicate that approximately 3 days are required for the risk of false-positive results due to meat consumption to subside.[49] Although current recommendations advise avoiding red meat for at least 3 days before testing, the duration required to eliminate the risk may vary depending on clinical circumstances and bowel habits. However, some studies have reported no significant effect of red meat on occult blood testing.[50]

A meta-analysis concluded that dietary restriction may not be necessary for guaiac-based FOBTs.[51] Ascorbic acid (vitamin C) can interfere with the oxidation of α-guaiaconic acid due to its reducing properties. Ingestion of 1 to 2 grams daily of this nutrient may produce false-negative results.[52] In vitro studies suggest that normal dietary vitamin C intake is unlikely to generate false-positive results.[53] A recent study demonstrated that consumption of 60 mg of vitamin C or 500 mL of orange juice (approximately 350 mg of vitamin C) generated variable results, with high-dose supplementation resulting in false-negative outcomes.[54]

Use of povidone-iodine antiseptic solutions is associated with false-positive results in guaiac-based FOBT.[55] In vitro studies demonstrated that as little as 0.005 mL of a 1:1000 dilution of this solution can yield a false-positive result. This interference is attributable to iodine, which oxidizes α-guaiaconic acid.[56] Application of povidone-iodine to the perianal area or, during urinary catheterization, the urinary tract should be avoided before performing guaiac-based FOBT.

Medications such as aspirin, nonsteroidal anti-inflammatory drugs (eg, ibuprofen, naproxen), corticosteroids, phenylbutazone, and cancer chemotherapeutic agents, as well as excessive alcohol consumption, can generate positive reactions secondary to gastric irritation and subsequent blood loss. Recent studies indicate that low-dose aspirin does not significantly affect FOBT outcomes.[57] Research shows no significant difference in FOBT positivity between patients on anti-inflammatory medications like aspirin and those not on such drugs, implying that stopping these agents before testing may not be necessary.[58]

Toilet sanitizers may also interfere with FOBT. Chlorine-generating sanitizers produce false-positive results in guaiac-based assays.[59] Nonchlorine-generating sanitizers can reduce the sensitivity of immunological detection of hemoglobin.[60]

Complications

FOBT is not associated with any major complications. Adverse effects are limited to transient discomfort related to stool handling or collection procedures.

Patient Safety and Education

FOBT results are primarily influenced by patient preparation, making adherence to instructions essential. Certain foods can interfere with test outcomes. Therefore, a restricted diet is often recommended for 48 to 72 hours before testing. Additionally, medications such as anticoagulants, aspirin, colchicine, nonsteroidal anti-inflammatory drugs, iron preparations, and corticosteroids should be avoided for at least 7 days before testing.

Clinical Significance

In the U.S., CRC is the 3rd leading cause of cancer-related deaths in men and the 4th in women. When both sexes are considered together, the condition becomes the 2nd most common cause of cancer mortality. The disease affects all populations, irrespective of race, ethnicity, gender, or socioeconomic status.[61]

CRC is most frequently diagnosed in adults aged 65 to 74. Inadequate screening contributes to delayed diagnosis and treatment.[62] FOBT constitutes 1 of several validated methods for CRC screening in asymptomatic patients. This diagnostic tool facilitates early detection by identifying individuals who require follow-up evaluation with procedures such as colonoscopy. FOBT is not indicated for high-risk or symptomatic patients who should receive prompt referral to a gastroenterologist for further evaluation and management.

Improper or indiscriminate use of FOBT can lead to unnecessary diagnostic procedures, increased healthcare costs, and prolonged hospitalizations. Consequently, FOBT should be performed only when clinically indicated, and multiple professional organizations emphasize the importance of educating healthcare providers regarding appropriate indications.

The U.S. Preventive Services Task Force concludes with high certainty that CRC screening in adults aged 50 to 75 provides a substantial net benefit, whereas screening in adults aged 45 to 49 provides a moderate net benefit.[63] The U.S. Preventive Services Task Force further concludes with moderate certainty that screening in adults aged 76 to 85 who have undergone prior screening offers a small net benefit. These assessments of net benefit apply to stool-based tests with high sensitivity, colonoscopy, computed tomography colonography, and flexible sigmoidoscopy.[64] 

Current guidelines from the American College of Gastroenterology recommend initiating CRC screening at age 45 for average-risk individuals.[65] In patients with a 1st-degree relative diagnosed with advanced adenomas or CRC before age 60, screening should begin at age 40 or 10 years before the age at diagnosis of the youngest affected relative, whichever is earlier. For patients with 1st-degree relatives diagnosed after reaching age 60, screening may begin at the standard age of 50.[66]

Recommendations also favor replacing guaiac-based FOBT with FIT due to superior sensitivity and specificity.[67] FIT targets human globin, predominantly derived from lower gastrointestinal bleeding, and demonstrates improved CRC detection compared with FOBT. FIT does not require dietary modifications, thereby enhancing patient adherence.[68]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Song LL, Li YM. Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests. World J Gastrointest Oncol. 2016 Nov 15;8(11):793-800. [PMC free article: PMC5108981] [PubMed: 27895817]

2.

Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015 Oct;64(10):1637-49. [PubMed: 26041752]

3.

Medical Advisory Secretariat. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9(10):1-40. [PMC free article: PMC3377532] [PubMed: 23074514]

4.

Khakimov N, Khasanova G, Ershova K, Gibadullina L, Vetkina T, Lobisheva G, Chumakova A. Screening for colon cancer: A test for occult blood. Int J Risk Saf Med. 2015;27 Suppl 1:S110-1. [PubMed: 26639687]

5.

Li JN, Yuan SY. Fecal occult blood test in colorectal cancer screening. J Dig Dis. 2019 Feb;20(2):62-64. [PubMed: 30714325]

6.

Wielandt AM, Hurtado C, Moreno M, Zárate A, López-Köstner F. [Fecal occult blood test for colorectal cancer screening]. Rev Med Chil. 2021 Apr;149(4):580-590. [PubMed: 34479346]

7.

Thomas WM, Pye G, Hardcastle JD, Mangham CM. Faecal occult blood screening for colorectal neoplasia: a randomized trial of three days or six days of tests. Br J Surg. 1990 Mar;77(3):277-9. [PubMed: 2322789]

8.

Elsafi SH, Alqahtani NI, Zakary NY, Al Zahrani EM. The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings. Clin Exp Gastroenterol. 2015;8:279-84. [PMC free article: PMC4573202] [PubMed: 26392783]

9.

Sokoro A, Singh H. Fecal Occult Blood Test for Evaluation of Symptoms or for Diagnostic Testing. Am J Gastroenterol. 2020 May;115(5):679-680. [PubMed: 32058343]

10.

Young GP, Sinatra MA, St John DJ. Influence of delay in stool sampling on fecal occult blood test sensitivity. Clin Chem. 1996 Jul;42(7):1107-8. [PubMed: 8674197]

11.

Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. World J Gastroenterol. 2017 May 28;23(20):3632-3642. [PMC free article: PMC5449420] [PubMed: 28611516]

12.

Kaur K, Zubair M, Adamski JJ. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 1, 2025. Fecal Occult Blood Test. [PubMed: 30725823]

13.

Lee MW, Pourmorady JS, Laine L. Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020 May;115(5):662-670. [PubMed: 31972617]

14.

Shaukat A, Church TR, Mandel JS. Guaiac Fecal Occult Blood Test and Reduction in Colorectal Cancer Incidence. Clin Gastroenterol Hepatol. 2021 Oct;19(10):2217. [PubMed: 33965576]

15.

Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010 Sep;105(9):2017-25. [PubMed: 20502450]

16.

Greenwald B. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening. Gastroenterol Nurs. 2005 Mar-Apr;28(2):90-6. [PubMed: 15832108]

17.

Wilkins T, McMechan D, Talukder A. Colorectal Cancer Screening and Prevention. Am Fam Physician. 2018 May 15;97(10):658-665. [PubMed: 29763272]

18.

Yuan SY, Wu W, Fu J, Lang YX, Li JC, Guo Y, Wang YN, Qian JM, Li JN. Quantitative immunochemical fecal occult blood test for neoplasia in colon cancer screening. J Dig Dis. 2019 Feb;20(2):78-82. [PubMed: 30714346]

19.

Ou CH, Kuo FC, Hsu WH, Lu CY, Yu FJ, Kuo CH, Wang JY, Wu MT, Shiea J, Wu DC, Hu HM. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan. J Dig Dis. 2013 Sep;14(9):474-83. [PubMed: 23701988]

20.

Quintero E. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?]. Gastroenterol Hepatol. 2009 Oct;32(8):565-76. [PubMed: 19577340]

21.

Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005 Nov;100(11):2519-25. [PubMed: 16279909]

22.

Kościelniak-Merak B, Radosavljević B, Zając A, Tomasik PJ. Faecal Occult Blood Point-of-Care Tests. J Gastrointest Cancer. 2018 Dec;49(4):402-405. [PMC free article: PMC6208834] [PubMed: 30232694]

23.

Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, Messersmith H, Lewis N. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012 Mar;26(3):131-47. [PMC free article: PMC3299236] [PubMed: 22408764]

24.

Young GP, Cole SR. Which fecal occult blood test is best to screen for colorectal cancer? Nat Clin Pract Gastroenterol Hepatol. 2009 Mar;6(3):140-1. [PubMed: 19174764]

25.

Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med. 1985 May 30;312(22):1422-8. [PubMed: 3873009]

26.

St John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JC. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 1993 Jun;104(6):1661-8. [PubMed: 8500724]

27.

Wu CI, Tsai CC, Lu CC, Wu PC, Wu DC, Lin SY, Shiea J. Diagnosis of occult blood in human feces using matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. Clin Chim Acta. 2007 Sep;384(1-2):86-92. [PubMed: 17662705]

28.

Lin SY, Shih SH, Wu DC, Lee YC, Wu CI, Lo LH, Shiea J. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the detection of hemoglobins as the protein biomarkers for fecal occult blood. Rapid Commun Mass Spectrom. 2007;21(20):3311-6. [PubMed: 17879387]

29.

Simon JB. Fecal occult blood testing: clinical value and limitations. Gastroenterologist. 1998 Mar;6(1):66-78. [PubMed: 9531118]

30.

Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, Hou X. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017 Jun 01;7(1):2669. [PMC free article: PMC5453945] [PubMed: 28572616]

31.

Dalle I, Geboes K. Vascular lesions of the gastrointestinal tract. Acta Gastroenterol Belg. 2002 Oct-Dec;65(4):213-9. [PubMed: 12619428]

32.

Papaconstantinou HT, Thomas JS. Bacterial colitis. Clin Colon Rectal Surg. 2007 Feb;20(1):18-27. [PMC free article: PMC2780149] [PubMed: 20011357]

33.

Moralidis E, Papanastassiou E, Arsos G, Chilidis I, Gerasimou G, Gotzamani-Psarrakou A. A single measurement with (51)Cr-tagged red cells or (125)I-labeled human serum albumin in the prediction of fractional and whole blood volumes: an assessment of the limitations. Physiol Meas. 2009 Jul;30(7):559-71. [PubMed: 19458409]

34.

Pineda AA, Dharkar DD, Wahner HW. Clinical evaluation of a 51Cr-labeled red blood cell survival test for in vivo blood compatibility testing. Mayo Clin Proc. 1984 Jan;59(1):25-30. [PubMed: 6694429]

35.

Macrae FA, St John DJ, Caligiore P, Taylor LS, Legge JW. Optimal dietary conditions for hemoccult testing. Gastroenterology. 1982 May;82(5 Pt 1):899-903. [PubMed: 7060911]

36.

St John DJ, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA. Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Intern Med. 1992 Sep 01;117(5):376-82. [PubMed: 1503328]

37.

Rosenfield RE, Kochwa S, Kaczera Z, Maimon J. Nonuniform distribution of occult blood in feces. Am J Clin Pathol. 1979 Feb;71(2):204-9. [PubMed: 106720]

38.

Lynch NM, McHutchison JG, Young GP, Deacon M, St John DJ, Barraclough D. Gastrointestinal blood loss from a new buffered aspirin (Ostoprin): measurement by radiochromium and Hemoquant techniques. Aust N Z J Med. 1989 Apr;19(2):89-96. [PubMed: 2788406]

39.

Chowdhury ATMD, Longcroft-Wheaton G, Davis A, Massey D, Goggin P. Role of faecal occult bloods in the diagnosis of iron deficiency anaemia. Frontline Gastroenterol. 2014 Oct;5(4):231-236. [PMC free article: PMC5369754] [PubMed: 28839778]

40.

Harewood GC, McConnell JP, Harrington JJ, Mahoney DW, Ahlquist DA. Detection of occult upper gastrointestinal tract bleeding: performance differences in fecal occult blood tests. Mayo Clin Proc. 2002 Jan;77(1):23-8. [PubMed: 11794453]

41.

Wong C, Dubé C. More on fecal occult blood test misuse. Can J Gastroenterol Hepatol. 2014 Sep;28(8):419-20. [PMC free article: PMC4210231] [PubMed: 25229464]

42.

Konrad G, Katz A. Are medication restrictions before FOBT necessary?: practical advice based on a systematic review of the literature. Can Fam Physician. 2012 Sep;58(9):939-48. [PMC free article: PMC3440265] [PubMed: 22972722]

43.

Narula N, Ulic D, Al-Dabbagh R, Ibrahim A, Mansour M, Balion C, Marshall JK. Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review. Can J Gastroenterol Hepatol. 2014 Sep;28(8):421-6. [PMC free article: PMC4210232] [PubMed: 25014182]

44.

Caligiore P, Macrae FA, St John DJ, Rayner LJ, Legge JW. Peroxidase levels in food: relevance to colorectal cancer screening. Am J Clin Nutr. 1982 Jun;35(6):1487-9. [PubMed: 7081130]

45.

Griffith CD, Turner DJ, Saunders JH. False-negative results of Hemoccult test in colorectal cancer. Br Med J (Clin Res Ed). 1981 Aug 15;283(6289):472. [PMC free article: PMC1506216] [PubMed: 6790022]

46.

Meyer GW, Komadina K, Perucca P. Vegetable peroxidase is denatured by gastric acid: fresh vegetables do not cause false-positive stool Hemoccults in normal subjects. Gastroenterology. 1991 Sep;101(3):871. [PubMed: 1650322]

47.

Zwillenberg LO. [Prevention of false results in tests for occult blood in feces]. Schweiz Rundsch Med Prax. 1990 Apr 24;79(17):521-3. [PubMed: 2187220]

48.

Sinatra MA, St John DJ, Young GP. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Clin Chem. 1999 Jan;45(1):123-6. [PubMed: 9895348]

49.

Feinberg EJ, Steinberg WM, Banks BL, Henry JP. How long to abstain from eating red meat before fecal occult blood tests. Ann Intern Med. 1990 Sep 01;113(5):403-4. [PubMed: 2200323]

50.

Norfleet RG. Effect of diet on fecal occult blood testing in patients with colorectal polyps. Dig Dis Sci. 1986 May;31(5):498-501. [PubMed: 3009111]

51.

Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract. 2001 Jul-Aug;4(4):150-6. [PubMed: 11525101]

52.

Jaffe RM, Kasten B, Young DS, MacLowry JD. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med. 1975 Dec;83(6):824-6. [PubMed: 1200528]

53.

Garrick DP, Close JR, McMurray W. Detection of occult blood in faeces. Lancet. 1977 Oct 15;2(8042):820-1. [PubMed: 71626]

54.

Franke AA, Cooney RV, Henning SM, Custer LJ. Bioavailability and antioxidant effects of orange juice components in humans. J Agric Food Chem. 2005 Jun 29;53(13):5170-8. [PMC free article: PMC2533031] [PubMed: 15969493]

55.

Blebea J, McPherson RA. False-positive guaiac testing with iodine. Arch Pathol Lab Med. 1985 May;109(5):437-40. [PubMed: 3838658]

56.

Hait WN, Snepar R, Rothmen C. False-positive hematest due to povidone-iodine. N Engl J Med. 1977 Dec 15;297(24):1350-1. [PubMed: 917095]

57.

Greenberg PD, Cello JP, Rockey DC. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc. 1999 Nov;50(5):618-22. [PubMed: 10536315]

58.

Kahi CJ, Imperiale TF. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004 Dec 01;117(11):837-41. [PubMed: 15589487]

59.

Ahlquist DA, Schwartz S, Isaacson J, Ellefson M. A stool collection device: the first step in occult blood testing. Ann Intern Med. 1988 Apr;108(4):609-12. [PubMed: 3348567]

60.

Imafuku Y, Nagai T, Yoshida H. The effect of toilet sanitizers and detergents on immunological occult blood tests. Clin Chim Acta. 1996 Sep 30;253(1-2):51-9. [PubMed: 8879838]

61.

Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. [PMC free article: PMC6791134] [PubMed: 31616522]

62.

Petre-Mandache CB, Margaritescu DN, Mitrut R, Kamal AM, Padureanu V, Cucu MG, Mitrut P. Risk Factors and Genetic Predisposition in Colorectal Cancer: A Study on Young and Old Adults. Curr Health Sci J. 2021 Jan-Mar;47(1):84-88. [PMC free article: PMC8200615] [PubMed: 34211752]

63.

US Preventive Services Task Force. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 May 18;325(19):1965-1977. [PubMed: 34003218]

64.

Ng K, May FP, Schrag D. US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty. JAMA. 2021 May 18;325(19):1943-1945. [PubMed: 34003238]

65.

de Kanter C, Dhaliwal S, Hawks M. Colorectal Cancer Screening: Updated Guidelines From the American College of Gastroenterology. Am Fam Physician. 2022 Mar 01;105(3):327-329. [PubMed: 35289558]

66.

Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021 Mar 01;116(3):458-479. [PubMed: 33657038]

67.

Day LW, Bhuket T, Allison J. FIT testing: an overview. Curr Gastroenterol Rep. 2013 Nov;15(11):357. [PubMed: 24218070]

68.

Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015 Aug;64(8):1327-37. [PubMed: 26041750]

Disclosure: Kuljit Kaur declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Zubair declares no relevant financial relationships with ineligible companies.

Disclosure: Jamie Adamski declares no relevant financial relationships with ineligible companies.